Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanostart-holding MagForce AG announces company restructuring and revised corporate strategy for 2012

Abstract:
- Greater emphasis on clinical development to provide key physicians with access to NanoTherm therapy
- Start of post marketing glioblastoma study Q3 2012 to support expanded market acceptance with leading medical experts
- Enhanced activities for international partnerships and initiation of discussions with FDA
- Focus on development partnerships and strategic investors to expand patient access and further reduce development costs
- Significant decrease in operating expenses expected in 2012 through headcount reduction

Nanostart-holding MagForce AG announces company restructuring and revised corporate strategy for 2012

Berlin / Frankfurt Germany | Posted on March 26th, 2012

Nanostart (OTCQX:NASRY)-holding MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company focusing on nanomedicine in oncology announced today the company's restructuring and revised corporate strategy for 2012. The company reduced its headcount from 52 employees (year-end 2011) to 30 (April 1, 2012) and expects a significant reduction in company expenses in 2012 as compared to 2011. The implemented cost reductions will enable the company to work more effectively and concentrate on clinical development activities to support the market introduction of NanoTherm® therapy.

MagForce has revised its corporate strategy to put more emphasis on clinical development and its synergies with Marketing and Sales. The company has received EU approval for its technology, NanoTherm® therapy, for the treatment of brain tumors. Product revenues in 2011 were lower than expected due to the lack of involvement among leading medical experts in the development of the therapy. MagForce is now working closely with these key opinion leaders who have agreed to participate in a post-approval multi-center study to validate the novel technology in the medical community and gain first-hand experience.

"Our successful capital increase earlier this month along with reductions in expenditures will allow us to initiate both a glioblastoma post-market authorization study along with a study in prostate carcinoma this year. These upcoming trials, conducted in centers throughout Germany, will lay the foundation for wider acceptance of the therapy and expanded commercial use," said Dr. Andreas Jordan, Management Board and founder of MagForce. "In addition, we are in discussion with international companies and investors for strategic partnerships to share in the development costs and support international market approvals, including for the US market."

"I am delighted to be working closely with leading European key opinion leaders who are pleased to support us in the further development of NanoTherm® therapy and participate in Magforce clinical studies," said Prof. Dr. Hoda Tawfik, VP Clinical Development and Medical Affairs. "Within the multi-center studies, we expect to place two to three new NanoActivator therapy systems in strategic centers before the end of this year."

In 2012, MagForce is pursuing international partnerships, specifically in the US, and plans to initiate discussions with the FDA (Food and Drug Administration). Furthermore, the company is in discussion with strategic investors who were not able to participate in recently announced fully-subscribed capital increase, but are interested in future investment opportunities with the company.

####

About Nanostart AG
Nanostart AG (OTCQX: NASRY) headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government.

About MagForce:
MagForce AG (XETRA: MF6) is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.

For more information, please click here

Contacts:
Nanostart AG
Dr. Hans Joachim Duerr
Head of Corporate Communications
Goethestrasse 26-28
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150

Copyright © Nanostart AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Possible Futures

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Investments/IPO's/Splits

Harris & Harris Group Issues Letter to Shareholders and Information for Shareholder Call on Tuesday, November 15, 2016 November 14th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Mechanism for sodium storage in 2-D material: Tin selenide is an effective host for storing sodium ions, making it a promising material for sodium ion batteries October 27th, 2016

Enterprise In Space Partners with Sketchfab and 3D Hubs for NewSpace Education October 13th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project